STOCKSCOUTER
StockScouter Premium
StockScouter Screener and Portfolios are now in our premium offering.
Learn more or Get it now! Stockscouter Portfolio performance
Learn more or Get it now! Stockscouter Portfolio performance
RUBY RUBIUS THERAPEUTICS INCORPORATED StockScouter® Report
4
StockScouter® Score
RUBIUS THERAPEUTICS INCORPORATED, a micro cap company in the healthcare sector, is expected to underperform the market over the next six months with higher than average risk
10 is the best possible rating. Learn more.
Summary
Positives
- Earnings growth in the past year has accelerated rapidly compared to earnings growth in the past three years. Positive
- The multi-period measure of relative price change and consistency is above average. Positive/Neutral
Concerns
- Moving average analysis for RUBY suggests weak price movement over the medium term. Negative
- Two or more executives, directors or major shareholders – including one high-level executive –sold a small number of shares recently. Very negative
Short-term Outlook
Over the next 1-2 months, StockScouter forecasts that micro cap stocks will be out of favor, stocks will be , and healthcare stocks will be out of favor.
Expected Risk/Return
Core Model Grades
B
D
N/A
C